Calquence BTK inhibitors and Covid 19

You may have heard that A very preliminary study using the btk inhibitor Calquence shows promise in treating Severe Covid patients. A randomized Control trial is in effect to assess its efficacy.

https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html

The pandemic is over when we have a effective treatment for the severe Covid patients. This is very promising especially if can be mixed with a cocktail of other drugs such as the anti virals, anti coags, anti oxidants and or other anti inflammatory drugs.

We didn’t understand this virus pathological effects from its attacking the endothelium. There are many other promising treatments coming up very soon that will allow us to treat this virus. It’s not 1918. We are much more advanced than 1918.

This topic was automatically closed 6 days after the last reply. New replies are no longer allowed.

“Let your conversation be always full of grace, seasoned with salt, so that you may know how to answer everyone.” -Colossians 4:6

This is a place for gracious dialogue about science and faith. Please read our FAQ/Guidelines before posting.